ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
enkayess
|
39 |
6.3K |
4 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
39
|
6.3K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
enkayess
|
39 |
6.3K |
5 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
39
|
6.3K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
enkayess
|
15 |
4.6K |
17 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
15
|
4.6K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
enkayess
|
85 |
20K |
17 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
enkayess
|
495 |
112K |
8 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
495
|
112K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
enkayess
|
495 |
112K |
19 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
495
|
112K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
enkayess
|
495 |
112K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
495
|
112K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
enkayess
|
58 |
15K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
15K
|
11
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
enkayess
|
4 |
1.2K |
1 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
4
|
1.2K
|
1
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Company Presentation - Investor Insights
|
|
enkayess
|
77 |
18K |
4 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
77
|
18K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
enkayess
|
239 |
63K |
17 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
63K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
enkayess
|
239 |
63K |
28 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
63K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
enkayess
|
239 |
63K |
9 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
63K
|
9
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Company Presentation - Investor Insights
|
|
enkayess
|
77 |
18K |
7 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
77
|
18K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
enkayess
|
317 |
82K |
12 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
317
|
82K
|
12
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
enkayess
|
4 |
1.2K |
2 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
4
|
1.2K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
enkayess
|
261 |
71K |
5 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
71K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
enkayess
|
317 |
82K |
16 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
317
|
82K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
enkayess
|
222 |
47K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
222
|
47K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
enkayess
|
1.4K |
358K |
13 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
1.4K
|
358K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
enkayess
|
1.4K |
358K |
5 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
1.4K
|
358K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
enkayess
|
1.4K |
358K |
9 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
1.4K
|
358K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
enkayess
|
323 |
76K |
27 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
323
|
76K
|
27
|
|
ASX - By Stock
|
MGT Iron Ore |
Re:
MGT $ 1.00 TARGET PRICE 2024
|
|
enkayess
|
460 |
135K |
4 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
460
|
135K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
enkayess
|
323 |
76K |
21 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
76K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
109K |
25 |
24/01/24 |
24/01/24 |
ASX - By Stock
|
430
|
109K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
enkayess
|
111 |
34K |
14 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
111
|
34K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
enkayess
|
98 |
24K |
19 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
98
|
24K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
enkayess
|
98 |
24K |
32 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
98
|
24K
|
32
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.1M |
7 |
12/01/24 |
12/01/24 |
Charts
|
13K
|
5.1M
|
7
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
enkayess
|
13 |
5.0K |
0 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
13
|
5.0K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
109K |
13 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
109K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
109K |
5 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
430
|
109K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
109K |
34 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
430
|
109K
|
34
|
|
ASX - By Stock
|
MGT |
Re:
Ann: Appendix 3Y - Change of Directors' Interest Notice x 6
|
|
enkayess
|
4 |
1.0K |
6 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
4
|
1.0K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
enkayess
|
76 |
13K |
11 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
76
|
13K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
enkayess
|
355 |
69K |
14 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
355
|
69K
|
14
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.1M |
1 |
10/11/23 |
10/11/23 |
Charts
|
13K
|
5.1M
|
1
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.1M |
1 |
10/11/23 |
10/11/23 |
Charts
|
13K
|
5.1M
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at Emerging ASX Gems Conference
|
|
enkayess
|
82 |
18K |
16 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
82
|
18K
|
16
|
|
ASX - By Stock
|
MGT |
Re:
Ann: Razorback Iron Ore Project Update
|
|
enkayess
|
133 |
37K |
0 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
133
|
37K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
enkayess
|
28 |
5.1K |
3 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
28
|
5.1K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
enkayess
|
78 |
21K |
16 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
78
|
21K
|
16
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Investor Education Update & Webinar
|
|
enkayess
|
2 |
978 |
0 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
2
|
978
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
enkayess
|
396 |
84K |
5 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
396
|
84K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
enkayess
|
396 |
84K |
9 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
396
|
84K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
enkayess
|
218 |
50K |
9 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
218
|
50K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
enkayess
|
396 |
84K |
6 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
84K
|
6
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Breakthrough Results a Major Step Towards Commercialisation
|
|
enkayess
|
74 |
26K |
3 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
74
|
26K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
enkayess
|
218 |
50K |
3 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
50K
|
3
|
|